A securities class action has been filed against The Chemours Company (CC) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Chemours securities between February 20, 2026 through August 4, 2026. This case has been filed in the USDC – DE.
Chemours offers a range of industrial and specialty chemical products for markets including, as relevant here, refrigeration and air conditioning. Chemours reports financial results from its sales of such products, including Opteon™, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint”, in its Thermal & Specialized Solutions segment.
In December 2020, the U.S. Congress enacted the American Innovation and Manufacturing Act (“U.S. AIM Act”), which directed the U.S. Environmental Protection Agency to reduce the human impact on climate change by overseeing the transition to alternative refrigerants that present a lesser impact to the ozone layer than legacy refrigerants.
At all relevant times, Defendants represented to investors that “[g]rowth in our Thermal & Specialized Solutions segment is supported in part by the adoption of the [U.S. AIM Act] in the U.S.”
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
On August 4, 2026, after market hours, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.